Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (247)	4/21/1999 4:49:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1475

MEDI reported. Partner has $194 million in cash, hitting on all cylinders. No mention of anti-CD2....... Dr. Hockmeyer added that, ''Beyond Synagis(TM) we continue to make excellent progress with the development of our R&D pipeline, with five additional product candidates currently in clinical trials and two new product candidates expected to enter the clinic by the end of this year. While much of the focus is currently on our commercial success with Synagis(TM), it is important to remember that our R&D base has also never been stronger.''